secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aquestive Therapeutics, Inc. (AQST)
CIK:        0001398733
Form:       8-K
Filed at:   2024-12-02T23:59:59+00:00
Accession:  0001628280-24-049497
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aquestive receives positive FDA feedback for Anaphylm; reaffirms Q1 2025 NDA submission
--------------------------------------------------------------------------------

- FDA agreed on NDA content, safety evaluation, and pediatric trial plan; no additional adult trials needed.
- Single-dose pediatric trial commenced in U.S. and Canada in December 2024.
- FDA noted an advisory committee meeting may be necessary due to new route of administration.
- Reaffirms NDA submission guidance for Q1 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024049497/0001628280-24-049497-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1398733/000162828024049497/aqst-20241202.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-049497

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer